At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 604 enrolled
Drug / intervention
LEO 90100 +1 moredrug
Likely dose
LEO 90100 15 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomised, Investigator-blind, Active-controlled, Parallel Group, Multicentre Trial Comparing the Efficacy and Safety of 4-weeks Treatment With LEO 90100 and Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating LEO 90100 and Daivobet® ointment for Stable Plaque Psoriasis. Completed, enrolled 604 participants across 38 sites.
Detailed Summary
This study is conducted to assess the efficacy and safety of LEO 90100 when used on the body for the treatment of stable plaque psoriasis in native adult Chinese subjects, compared to Daivobet® ointment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStable Plaque Psoriasis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
Enrollment StartJun 2023
First PostedJun 2023
Primary CompletionFeb 2024
Study CompletionMar 2024
TodayJul 2026
First PostedJun 26, 2023
Enrollment StartJun 21, 2023
Primary CompletionFeb 23, 2024
Study CompletionMar 5, 2024
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.0 years ago
Interventions
LEO 90100drug
Subjects will apply LEO 90100 topically; up to 15 g per day (or 105 g per week).
Daivobet® ointmentdrug
Subjects will apply Daivobet® ointment topically; up to 15 g per day (or 105 g per week).